Skip to main content

Table 1 Characteristics of patients in irAE and non-irAE groups

From: Correlation between immune-related adverse events and prognosis in patients with gastric cancer treated with nivolumab

  All patients
No. (%)
irAE group
No. (%)
non-irAE group
No. (%)
P-value
Total N 65 14 51  
Age
  < 65 28 (43.1) 4 (28.6) 24 (47.1) 0.24
  ≥ 65 37 (56.9) 10 (71.4) 27 (52.9)
Sex
 Female 14 (21.5) 6 (42.9) 8 (15.7) 0.06
 Male 51 (78.5) 8 (57.1) 43 (84.3)
ECOG PS
 0 7 (10.8) 4 (28.6) 3 (5.9) 0.03
  ≥ 1 58 (89.2) 10 (71.4) 48 (94.1)
Number of metastatic sites
  < 2 16 (24.6) 3 (21.4) 13 (25.5) 1.00
  ≥ 2 49 (75.4) 11 (78.6) 38 (74.5)
ALP
 Low 31 (47.7) 7 (50.0) 24 (47.1) 1.00
 High 34 (52.3) 7 (50.0) 27 (52.9)
Histologic type
 Intestinal 34 (52.3) 9 (64.3) 25 (49.0) 0.37
 Diffuse 31 (47.7) 5 (35.7) 26 (51.0)
HER2 status
 Positive 13 (20.0) 11 (78.6) 41 (80.4) 1.00
 Negative 52 (80.0) 3 (21.4) 10 (19.6)
Disease status
 Stage IV 32 (49.2) 4 (28.6) 28 (54.9) 0.13
 Recurrence 33 (50.8) 10 (71.4) 23 (45.1)
NLR
 Low (< 4) 37 (56.9) 8 (57.1) 29 (56.9) 0.96
 High (≥4) 28 (43.1) 6 (42.9) 22 (43.1)
Baseline blood cell count median (range)
 WBC (/μL) 3900 (2500–19,900) 4900 (3700–14,300) 6300 (2500–19,900) 0.06
 Neutrophil (/μL) 2570 (1310–18,710) 3210 (2180–9880) 4290 (1310–18,710) 0.06
 Lymphocyte (/μL) 965 (400–3230) 1080 (650–2820) 1080 (650–3230) 0.67
 Eosinophil (/μL) 91 (0–839) 121 (18–684) 91 (0–839) 0.22
 NLR 2.60 (1.00–31.2) 2.92 (1.00–6.33) 3.54 (1.16–31.2) 0.21
  1. ALP alkaline phosphatase, ECOG PS Eastern Cooperative Oncology Group Performance Status, irAE immune-related adverse event, NLR neutrophil-to-lymphocyte ratio, WBC white blood cell
\